

## Workshop on Clinical Translation of Molecular Imaging Probes and Technology

August 2, 2013 Lister Hill Auditorium National Institutes of Health Bethesda, Maryland

## <u>Agenda</u>

| 7:45 – 8:00 a.m.   | Registration   |
|--|--|
| 8:00 – 8:10 a.m.   | Welcoming Remarks Roderic Pettigrew, Ph.D., M.D., Director, NIBIB  |
| 8:10 – 8:15 a.m.   | Introduction<br>Christina Liu, Ph.D., P.E., NIBIB  |
| Session I: Current Challenges and Needs for Clinical Research and Patient Care Chair: Steven Krosnick, M.D., NIBIB |  |
| 8:15 – 8:35 a.m.   | <b>Development of New Imaging Probes for CVD: Challenges and Possible Benefits</b> Lynne Johnson, M.D., Columbia University/New York - Presbyterian Hospital |
| 8:40 – 9:00 a.m.   | Clinical Needs for Molecular Imaging in Diabetic and Metabolic Diseases<br>Maren Laughlin, Ph.D., NIDDK, NIH   |
| 9:05 – 9:25 a.m.   | Molecular Imaging Needs in Translational and Clinical Neuroscience<br>Kirk Frey, M.D., Ph.D., University of Michigan   |
| 9:30 – 9:50 a.m.   | Imaging Chemokine Receptors: The Case of CXCR4 Joshua Farber, M.D., NIAID, NIH   |
| 9:55 – 10:15 a.m.  | BREAK  |
|  | vances and Potential in Molecular Probe Design<br>air: Richard Conroy, Ph.D., NIBIB  |
| 10.15 10.25  | December A december to MD December Anna Wa Thomas West 9   |

| 10:15 – 10:35 a.m. | Recent Advances in MR Probes: Are We There Yet? Thomas Meade, Ph.D., Northwestern University |
|--------------------|--|
| 10:40 – 11:00 a.m. | <b>Unmet Needs in PET Imaging of Neurodegenerative Diseases</b>                              |

Chester Mathis, Ph.D., University of Pittsburgh

11:05 – 11:25 a.m. Ultrasound-based Molecular Imaging: Advantages, Limitations and Outlook Stanislav Emelianov, Ph.D., University of Texas at Austin 11:30 – 11:50 a.m. Multi-modality and Multi-functional Molecular Imaging Agents Martin Pomper, M.D., Ph.D., Johns Hopkins University Panel Discussion / Moderator: Richard Conroy, Ph.D., NIBIB 11:55 – 12:15 p.m. All Session I and Session II Speakers 12:15 – 1:05 p.m. LUNCH **Session III: Current Challenges and Needs for Industry and Pharmaceutical Companies** Chair: Christina Liu, Ph.D., P.E., NIBIB 1:05 - 1:25 p.m.**NCI Programs in Translational Molecular Imaging Research** Paula Jacobs, Ph.D., NCI, NIH 1:30 - 1:50 p.m. The Expanding Use of PET Molecular Imaging, the Current Trends and **Challenges for Pharmaceutical Companies** Kevin Maresca, Ph.D., Pfizer, Inc. 1:55 - 2:15 p.m.Use of Exploratory IND for Early Phase Clinical Trials Using PET or **SPECT Imaging** Gilles Tamagnan, Ph.D., Molecular Neuroimaging, Inc. 2:20 - 2:40 p.m. **BREAK Session IV: Clinical Translation of Molecular Imaging Probes** Chair: Antonio Sastre, Ph.D., NIBIB 2:40 - 3:00 p.m.Clinical Translation of Hyperpolarized Carbon-13 MRI Technology: Successes and Challenges Dan Vigneron, Ph.D., University of California, San Francisco 3:05 - 3:25 p.m. The Use of Imaging in Clinical Trials: CDER's Perspective Libero (Louis) Marzella, M.D., Ph.D., DMIP/CDER/FDA **Medicare Coverage of Molecular Imaging** 3:30 - 3:50 p.m. Louis Jacques, M.D., CMS Panel Discussion / Moderator: Antonio Sastre, Ph.D., NIBIB 3:55 - 4:20 p.m.All Session I, II, III, IV Speakers 4:20 - 4:30 p.m. **Concluding Remarks** Belinda Seto, Ph.D., Deputy Director, NIBIB